12,372 trials
Stage I Adrenal Cortical Carcinoma AJCC v7 · Stage II Adrenal Cortical Carcinoma AJCC v7 · Stage III Adrenal Cortical Carcinoma AJCC v7
Primary: Five Year Event-free Survival (EFS) — 0.86; 0.53; 0.51 Estimated probability five year EFS — p=0.44
Vaginal Atrophy
Primary: Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear — 60.66; 56.74; 59.54; 62.22 percentage of parabasal cells
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20) — 39.5; 65.9; 61.7 percentage of participants — p=0.001
Stress Urinary Incontinence
Primary: Subjective Cure of Urinary Incontinence at 12 Months After Surgery — 77; 72 Participants — p=0.43
Purpura, Thrombocytopenic, Idiopathic
Primary: Remission Duration — 3; 11 Participants
Breast Neoplasms
Primary: Percentage of Participants With Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples — 56.1; 44.4 Percentage of Participants — p=0.0126
Bacterial Infections
Primary: Percentage of Participants With Early Clinical Response at 48-72 Hours After the First Infusion of Study Drug in the ITT Analysis Set. — 75.3; 79.9 Percentage of…
Dry Eye Syndromes
Primary: Change From Baseline in the Ocular Surface Disease Index© (OSDI©) Score — 42.44; 40.43; -10.29; -7.48 Scores on a Scale
Nervous System Disorders
Primary: Assessment of the Long-term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs) — 102; 62; 47; 11 Participants
Non-Hodgkin's Lymphoma
Primary: Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed — 24.0; 16.8 percentage of participants with event — p=0.0012
Smoking Cessation
Primary: 7-day Point Prevalence Abstinence From Cigarettes — 68; 56; 56 Participants — p=0.54
Neuropathic Pain
Primary: Baseline Mean Pain Score — 6.41; 6.54 units on a scale
Primary Thrombocytopenia
Primary: Percentage of Responders — 80.6 Percentage of participants
Schizophrenia
Primary: Number of Events Recorded Based on Ziprasidone Side Effects Checklist During Randomized Trial — 633; 588 side effect events
Prostate Cancer
Primary: Overall Survival Rate (10-year) — 61.9; 56.8 percentage of patients — p=0.0309